Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion
Authors:
- 17 April 2019
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 8 (8) , 1601482
Abstract
Galectin-9 has emerged as a promising biological target for cancer immunotherapy due to its role as a regulator of macrophage and T-cell differentiation. In addition, its expression in tumor cells modulates tumor cell adhesion, metastasis, and apoptosis. Malignant mesothelioma (MM) is an aggressive neoplasm of the mesothelial cells lining the pleural and peritoneal cavities, and in this study, we found that both human MM tissues and mouse MM cells express high levels of galectin-9. Using a novel monoclonal antibody (mAb) (Clone P4D2) that binds the C-terminal carbohydrate recognition domain (CRD) of galectin-9, we demonstrate unique agonistic properties resulting in MM cell apoptosis. Furthermore, the P4D2 mAb reduced tumor-associated macrophages differentiation toward a protumor phenotype. Importantly, these effects exerted by the P4D2 mAb were observed in both human and mouse in vitro experiments and not observed with another antigalectin-9 specific mAb (clone P1D9) that engages the N-terminus CRD of galectin-9. In syngeneic murine models of MM, P4D2 mAb treatment inhibited tumor growth and improved survival, with tumors from P4D2-treated mice exhibited reduced infiltration of tumor-associated M2 macrophages. This was consistent with an increased production of inducible nitric oxide synthase, which is a major enzyme-regulating macrophage inflammatory response to cancer. These data suggest that using an antigalectin 9 mAb with agonistic properties similar to those exerted by galectin-9 may provide a novel multitargeted strategy for the treatment of mesothelioma and possibly other galectin-9 expressing tumors.Keywords
Funding Information
- National Institutes of Health (P30GM114737, P30GM103341, G12RR003061, G12MD007601, P20GM103466, U54MD007584, 5P30GM114737, P30 CA071789-17, and 2U54MD007601)
- National Institutes of Health (R01MH112457)
This publication has 49 references indexed in Scilit:
- IgBLAST: an immunoglobulin variable domain sequence analysis toolNucleic Acids Research, 2013
- The Glycan-Binding Protein Galectin-9 Has Direct Apoptotic Activity toward Melanoma CellsJournal of Investigative Dermatology, 2012
- Malignant mesothelioma: Facts, Myths, and HypothesesJournal of Cellular Physiology, 2011
- Regulation of cellular iron metabolismBiochemical Journal, 2011
- The N- and C-terminal carbohydrate recognition domains of galectin-9 contribute differently to its multiple functions in innate immunity and adaptive immunityMolecular Immunology, 2011
- Targeting Activating Transcription Factor 3 by Galectin-9 Induces Apoptosis and Overcomes Various Types of Treatment Resistance in Chronic Myelogenous LeukemiaMolecular Cancer Research, 2010
- Galectin–glycan lattices regulate cell-surface glycoprotein organization and signallingBiochemical Society Transactions, 2008
- Structural Features of Galectin-9 and Galectin-1 That Determine Distinct T Cell Death PathwaysJournal of Biological Chemistry, 2008
- Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectivesImmunological Reviews, 2008
- Development of highly stable galectins: Truncation of the linker peptide confers protease‐resistance on tandem‐repeat type galectinsFEBS Letters, 2005